论文部分内容阅读
目的探讨和对比瑞舒伐他汀与阿托伐他汀治疗早发冠心病急性心肌梗死的近期疗效。方法选取本院于2013年11月~2015年12月收治的120例早发冠心病急性心肌梗死患者为实验对象,随机分为A组60例和B组60例。A组给予瑞舒伐他汀治疗,B组给予阿托伐他汀治疗,比较两组患者的近期治疗效果。结果两组患者治疗前hs-CRP、血脂指标及心功能指标组间比较无统计学差异(P>0.05);治疗后两组患者hs-CRP、血脂指标及心功能指标较治疗前均有所改善,且A组hs-CRP及TC指标明显低于B组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀治疗早发冠心病急性心肌梗死的近期疗效优于阿托伐他汀,鉴于临床应用。
Objective To investigate and compare the short-term effects of rosuvastatin and atorvastatin on patients with acute myocardial infarction with premature coronary heart disease. Methods A total of 120 patients with acute myocardial infarction with premature coronary artery disease admitted from November 2013 to December 2015 in our hospital were selected and randomly divided into group A (60 cases) and group B (60 cases). Group A was treated with rosuvastatin, Group B was given atorvastatin, and the recent treatment was compared between the two groups. Results There was no significant difference in hs-CRP, serum lipids and cardiac function between the two groups before treatment (P> 0.05). After treatment, the hs-CRP, blood lipid and cardiac function indexes of both groups were higher than those before treatment (P <0.05), and the hs-CRP and TC indexes in group A were significantly lower than those in group B (P <0.05). Conclusion Rosuvastatin is superior to atorvastatin in the treatment of acute myocardial infarction with premature coronary heart disease. In view of its clinical application.